Roche (OTCQX:RHHBY) announces the commercial launch of uPath-L1, an automated digital pathology algorithm for non-small cell lung cancer. The company says the algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible, and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.